In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap